ALEPH Stats & Data

Evidence base is minimal: PiHKAL reports 5–10 mg oral with 6–8 h; plan conservatively and expect variability. The ALEPH family (e.g., ALEPH-2) shows erratic dose–response between individuals, so precise measurement and allergy testing (≤1 mg) are prudent. Slow onset (often >60 min) means redosing early can inadvertently create an overlong, overintense experience; wait at least 3–4 h before any change in dose. Driving and hazard work should be avoided for the entire active period and until baseline the next day—Shulgin notes basic tasks became ‘impossible’ at 10 mg. As a substituted amphetamine, sympathetic effects (tachycardia, mild hypertension, mydriasis, jaw tension) can occur; people with cardiovascular disease, uncontrolled hypertension, or a seizure disorder should avoid. Avoid non-oral routes; some sulfur-containing phenethylamines (e.g., 2C‑T‑7) have produced severe events and deaths when insufflated—while not the same drug, this signals risk for this structural family and argues strongly against nasal/IM/IV use. Combining with MAOIs is dangerous (unpredictable potentiation of monoamine effects); tramadol raises seizure and serotonin-syndrome risk; lithium and tricyclics have produced dangerous reactions with classical psychedelics—avoid. Because the substance is rare and markets are unregulated, adulteration/mislabeling is a significant risk: use professional drug checking (FTIR/GC-MS) where available; reagent kits are only preliminary screens. Set, setting, sleep, and nutrition matter: plan 12–24 h with no obligations, maintain light electrolytes, sip water regularly but avoid overhydration, and have a trusted sober sitter for first trials. Tolerance builds acutely and partially cross-tolerates with other psychedelics; allow at least 7–14 days between sessions to regain sensitivity. Very little pharmacokinetic data exist; half-life is unknown, so avoid stacking doses or combining with other stimulants.